


PGP9.5 Polyclonal Antibody

Product Details	
Size	100 µg
Species Reactivity	Human, Mouse, Rat
Published Species	Rat, Human, Mouse, Chicken
Host/Isotype	Rabbit / IgG
Class	Polyclonal
Type	Antibody
Conjugate	Unconjugated
Immunogen	Synthetic peptide derived from an internal region of the human USF-1 protein, isoforms 1 and 2, which are identical to mouse, rat, dog, and bovine isoform 1 and to mouse and dog isoform 2
Form	Liquid
Concentration	0.25 mg/mL
Purification	Antigen affinity chromatography
Storage buffer	PBS, pH 7.4
Contains	0.1% sodium azide
Storage conditions	-20°C
RRID	AB_2533355

Applications	Tested Dilution	Publications
Western Blot (WB)	1-3 µg/mL	2 Publications
Immunohistochemistry (IHC)	Assay-dependent	6 Publications
ELISA (ELISA)	Assay-dependent	-




PGP9.5 Antibody (38-1000)

FIG 2 C-terminal farnesylation of UCH-L1 is required for its association with the EBV primary oncogene LMP1. (A) Inhibition of cellular farnesylation reduces LMP1 association with UCH-L1. 293 cells were transfected with empty vector, GFP (green fluorescent protein), LMP1-Flag and UCH-L1 wild-type expression vectors and treated with DMSO and either UCH-L1 DUB activity inhibitor LDN-57444 or farnesyltransferase inhibitor FTI-277 (5 μM each). At 48 h after transfection, LMP1 was immunoprecipitated with anti-Flag-agarose beads. Band intensity was quantified by the use of ImageJ (<http://rsbweb.nih.gov/ij/>) software. The result shows less UCH-L1 in the LMP1 complexes under conditions of treatment with FTI-277 than was seen with the DMSO control or LDN-57444 treatment. (B) Inhibition of UCH-L1-specific farnesylation inhibits LMP1/UCH-L1 complex formation. 293 cells were transfected with LMP1-Flag and the UCH-L1 wild type or one of two UCH-L1 mutants: an enzymatically inactive mutant (C90S mutant) or UCH-L1 with a mutated farnesylation site (C220S mutant). Cells were harvested 48 h posttransfection for LMP1 complex formation analysis. After IP with anti-Flag-agarose beads, Western blot analysis was performed with the indicated antibodies. The results revealed less UCH-L1 C220S mutant than wild type or C90S mutant in complex with LMP1. Cell treatment validation info.


PGP9.5 Antibody (38-1000)

Antibody specificity was demonstrated by siRNA mediated knockdown of target protein. HeLa cells were transfected with PGP9.5 siRNA and loss of signal was observed in Western Blot using Anti-PGP9.5 Antibody (Product # 38-1000). Knockdown validation info.



PGP9.5 Antibody (38-1000)

Antibody specificity was demonstrated by CRISPR-Cas9 mediated knockout of target protein. A loss of signal was observed for target protein in PGP9.5/UCHL1 (KO) cell line compared to control cell line using Anti-PGP9.5/UCHL1 Polyclonal Antibody (Product # 38-1000). Knockout validation info.



View more figures on thermofisher.com

Western Blot (2)

<p>mSphere</p> <p>C-Terminal Farnesylation of UCH-L1 Plays a Role in Transport of Epstein-Barr Virus Primary Oncoprotein LMP1 to Exosomes.</p> <p>"Published figure using PGP9.5 polyclonal antibody (Product # 38-1000) in Western Blot"</p> <p>Authors: Kobayashi E, Aga M, Kondo S, Whitehurst C, Yoshizaki T, Pagano JS, Shackelford J</p>	<p>Species Human</p> <p>Dilution Not Cited</p> <p>Year 2019</p>
---	--

<p>International journal of molecular sciences</p> <p>Inhibition of UCH-L1 Deubiquitinating Activity with Two Forms of LDN-57444 Has Anti-Invasive Effects in Metastatic Carcinoma Cells.</p> <p>"Published figure using PGP9.5 polyclonal antibody (Product # 38-1000) in Western Blot"</p> <p>Authors: Kobayashi E, Hwang D, Bheda-Malge A, Whitehurst CB, Kabanov AV, Kondo S, Aga M, Yoshizaki T, Pagano JS, Sokolsky M, Shakelford J</p>	<p>Species Not Applicable</p> <p>Dilution Not Cited</p> <p>Year 2019</p>
--	---

Immunohistochemistry (6)

<p>Diabetes</p> <p>NLRP3 Promotes Diabetic Bladder Dysfunction and Changes in Symptom-Specific Bladder Innervation.</p> <p>"Published figure using PGP9.5 polyclonal antibody (Product # 38-1000) in Immunohistochemistry"</p> <p>Authors: Hughes FM, Hirshman NA, Inouye BM, Jin H, Stanton EW, Yun CE, Davis LG, Routh JC, Purves JT</p>	<p>Species Not Applicable</p> <p>Dilution Not Cited</p> <p>Year 2019</p>
---	---

<p>American journal of physiology. Renal physiology</p> <p>Bladder decompensation and reduction in nerve density in a rat model of chronic bladder outlet obstruction are attenuated with the NLRP3 inhibitor glyburide.</p> <p>"38-1000 was used in Immunohistochemistry to suggest a critical role for NLRP3 in mediating bladder decompensation and nerve density during chronic BOO."</p> <p>Authors: Hughes FM, Sexton SJ, Ledig PD, Yun CE, Jin H, Purves JT</p>	<p>Species Rat</p> <p>Dilution 1:200</p> <p>Year 2019</p>
---	--

[View more IHC references on thermofisher.com](#)

More applications with references on thermofisher.com

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample. NO OTHER WARRANTIES, EXPRESS OR IMPLIED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT. BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPAIR, REPLACEMENT OF OR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SELLER'S SOLE OPTION. THERE IS NO OBLIGATION TO REPAIR, REPLACE OR REFUND FOR PRODUCTS AS THE RESULT OF (I) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (II) MISUSE, FAULT OR NEGLIGENCE OF OR BY BUYER, (III) USE OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS. Unless otherwise expressly stated on the Product or in the documentation accompanying the Product, the Product is intended for research only and is not to be used for any other purpose, including without limitation, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses, or any type of consumption by or application to human or animals.